Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Role of steroids in sustaining castration resistance

Frédéric Pouliot • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide

Frédéric Pouliot, MD, PhD, FRCSC, Research Center CHU de Quebec, Université Laval, Quebec, Canada, discusses the impact of extragonadal steroids on androgen receptor activity and sustaining castration-resistance in prostate cancers after primary therapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Frédéric Pouliot

PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC
2:45
ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC
Frédéric Pouliot • 15 Feb 2021
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
3:13
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
Frédéric Pouliot • 15 Feb 2021
OSPREY: PSMA-targeted PET-CT imaging in prostate cancer
2:02
OSPREY: PSMA-targeted PET-CT imaging in prostate cancer
Frédéric Pouliot • 13 Feb 2020

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals